GS
ADMA icon

GTS Securities’s ADMA Biologics ADMA Stock Holding History

GTS Securities’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-10,153
Closed -$91.5K – 1332
2026
Q1 		$91.5K Buy
+10,153
New +$160K ﹤0.01% 1428
2023
Q4 		– Sell
-10,571
Closed -$37.8K – 3997
2023
Q3 		$37.8K Buy
+10,571
New +$40.7K ﹤0.01% 3742

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

GTS Securities's ADMA Position: Q2 2026 in Review

GTS Securities sold out of ADMA Biologics (ADMA) in Q2 2026, closing a stake of 10,153 shares — an estimated $91.5K sold.

GTS Securities first reported a position in ADMA in Q3 2023 and held it in 2 quarters. The position peaked at $91.5K in Q1 2026. 322 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

  • GTS Securities reported no remaining ADMA Biologics position as of Q2 2026 after selling out during the quarter.
  • GTS Securities sold 10,153 ADMA Biologics shares in Q2 2026, an estimated $91.5K.
  • GTS Securities first reported a position in ADMA Biologics in Q3 2023 and held it in 2 quarters.
  • GTS Securities's ADMA Biologics position peaked at $91.5K in Q1 2026.
  • 322 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on GTS Securities's 13F filing for Q2 2026, filed 14 Aug 2026.